NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."
German healthcare data from 2004 through 2010 across a data set that included 146,000 patients shows dementia surfaced later among Actos patients.
The companies will develop Lilly's glucokinase activator LY2608204.
Editorial says risk is small, researchers say it could be clinically relevant.
The FDA approved the inhaled insulin last week.
The companies resubmitted SGLT2 inihibitor empagliflozen for FDA review. The EC approved the drug in May.
The American Diabetes Association has established an across-the-board recommendation that children 18 and younger should keep A1C levels at 7.5% or lower.
Yale researchers find patients are paying more money for newer diabetes medications as they gravitate towards insulin analogs, over human synthetic and animal insulin.
US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.
Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.
Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed diabetes patients tripled during that same time period.
Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.
Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.
Researchers found a correlation between patients feeling involved and how well they stick—if they stick—to their medication regimens.
The drugmaker is accused of burying cancer risks associated with the diabetes medication.
The regulator has put off the inhaled insulin's PDUFA date by three months.
The three-year collaboration includes $1.5 million for chronic kidney disease research.
The new indication would mean Tresiba and Victoza could be prescribed in tandem.
The Committee for Medicinal Products for Human Use endorses the SGLT2 inhibitor. The FDA refused to approve the drug earlier this month because of manufacturing issues.
The issue: Boehringer's manufacturing site. The FDA is not asking for new clinical studies.
Spurred by a 2013 report of a possible link between drugs like Merck's Januvia and pancreatitis or pancreatic cancer, the FDA and EMA said they have not found a definitive link but will continue to collect data.
Phase-III results, top-lined today, show Lilly's investigational GLP-1 drug is well-positioned to eat into the multi-billion-dollar diabetes market now dominated by Novo Nordisk.
Merck announced this week that its insulin glargine biosimilar, being developed with Samsung and Biogen Idec, would soon enter Phase-III trials.
Governments have been courting industry investment, reports the Wall Street Journal.
The regulator says a 2013 study that indicated a higher rate of heart failure compared to placebo—but not death—has prompted a second look at the diabetes medication.
A six-month pilot program at the University of Chicago improved glycemic control and engaged patients and HCPs through one key device: a mobile phone.
Constant exchange rates provide a positive framework for quarterly and year-end totals, whereas straight percentages indicate lower sales.
Ten pharma companies will share money and biomarker research under an NIH collaboration.
The suit stalls Eli Lilly's biosimilar version of insulin glargine.
Higher prices helped insulate Q4 and annual sales, which fell and rose 2%, respectively. Lilly said its insulin glargine biosimilar will go nowhere if it is not substantially different from the competition.